USPTO serial 79209325
CELLENION
Reviewed by CopyMark Law Group
Reg. 5619510Status 708Registered
- Filing date
- Status date
- Registration date
- Dec 4, 2018
- Examiner
- TENG, SIMON
- Law office
- Historical data usage
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with CELLENION?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
DAVID M. TENER
DAVID M. TENER Caesar Rivise, PC500 Office Center DriveSuite 400Fort Washington, PA 19034Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | [ Monoclonal antibodies for scientific use; tagged antibodies for laboratory use; tagged antibodies for scientific use; monoclonal antibodies for scientific purposes; monoclonal antibodies for diagnostic use in scientific or research use other than for medical use; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; reagents for use in the development of hybridoma antibodies other than for medical or veterinary purposes; chemical reagents for use in the development of monoclonal antibodies other than for medical or veterinary purposes; proteins for detecting antibodies for scientific research other than for medical use; proteins for binding antibodies for scientific research other than for medical use; immunological antibodies, other than for medical use; monoclonal antibodies for industrial use; monoclonal antibody reagents, other than for medical use; stem cells for research purposes; stem cells for scientific purposes; stem cells for research or scientific purposes; stem cells other than for medical or veterinary purposes; collagen based ingredients for cosmetic preparations; hydrogel polymer coatings, namely, polymers and polymeric additives for use in the manufacture of food, pharmaceutical, cosmetics, nutraceutical, biomedical, medical products; lactic acid polymers; aqueous linear polymer gels; polymer composition coatings used in the manufacture of commercial and industrial goods other than paint; photo curable compositions comprising polymers; chemicals for use in polymerisations; ] polymer beads for use in manufacturing [ ; polymers of glucose for industrial use; water soluble polymers for industrial use; polymer based compounds for use in manufacture; amino acrylic polymers for use in manufacture; unprocessed polymers for use as reference standards in scientific research; polymeric chemical additives for use in the manufacture of cosmetics; unprocessed polymers for use in the analysis of nucleic acids; chemicals for use in performing nucleic acid polymerase chain reactions for scientific and research use other than for medical and veterinary uses; protein in raw material form for scientific research; proteins for use in the manufacture of cosmetics; enzymes for scientific, research, and industrial purposes other than for medical uses, namely, for detecting, labelling, and measuring protein fractions; recombinant DNA technology products, namely, protein in raw material form for scientific and medical research other than for medical use; biochemicals namely, polypeptides for in vitro research use; diagnostic reagents for in-vitro use other than medical; biochemicals for in vitro and in vivo scientific use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; diagnostic reagents for in-vitro laboratory use other than for medical or veterinary purposes; diagnostic reagents for scientific use; diagnostic preparations for scientific purposes; diagnostic preparations for scientific use; diagnostic preparations used in science; chemical diagnostic reagents for scientific use; in-vivo diagnostic reagents scientific use; diagnostic preparations for scientific or research use; diagnostic preparations for scientific or research use other than for medical use; reagents for use in diagnostic tests other than for medical or veterinary purposes; chemical reagents for use in diagnostic tests, other than for medical or veterinary use; media for cell culture for use in the biotechnological industry; media for cell culture for use in non-medical research laboratories; biological preparation for use in cell cultures other than for medical or veterinary use; cell culture media for laboratory, scientific, and research use other than for medical or veterinary uses; engineered biological tissues and tissue arrays, namely, human and animal organ, connective, epithelial, muscular, and nervous tissues and tissue arrays, for use in scientific and medical research; biologically compatible materials, namely, hydrogels used to create polymeric networks used in the manufacture of living tissue ] | ACTIVE | — |
| 005 | [ Biological implants, namely, a vital processed human or animal connective tissue; biological tissue for implantation; cells for medical use; human allograft tissue; living cells for medical use; implants for guided tissue regeneration, namely, biological tissue grafts; implants comprising living tissue; stem cells for medical or veterinary use; skin grafts; surgical implants grown from stem cells; surgical implants comprised of living tissues; surgical implants grown from stem cells living tissues; transdermal patches featuring smoking cessation preparations, caffeine for use as a stimulant, and vitamins for increasing energy; Transplants comprising living tissues; clinical, medical, and veterinary diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; living cells for veterinary use; stem cells for medical purposes; collagen for medical purposes; in vitro diagnostic preparations for medical use; reagents for in-vitro laboratory use for medical and veterinary purposes; medical, veterinary, and clinical medical diagnostic reagents; diagnostic preparations for veterinary use; diagnostic agents for medical purposes; diagnostic agents for pharmaceutical use; diagnostic preparations for medical purposes; diagnostic testing materials for medical use, namely, medical diagnostic reagents; diagnostic biomarker reagents for medical purposes; diagnostic chemical reagents for medical use; chemical diagnostic reagents for medical use; diagnostic preparations for medical or veterinary purposes; diagnostic preparations for medical and veterinary use; reagents for use in diagnostic tests for veterinary purposes; reagents and media for medical and veterinary diagnostic purposes; reagents for use in diagnostic tests for medical purposes; medical diagnostic reagents and assays for testing of body fluids; engineered biological tissues and organs, namely, human and animal cardiovascular, pulmonary, digestive, hepatobiliary, urological, renal, endocrine, connective, epithelial, muscular, and nervous tissue and organs, for medical purposes ] | SECTION 71 - CANCELLED | — |
| 009 | [ Biochips for research or scientific purposes; bioreactor for cell culturing; ] bioreactors for laboratory use; bioreactors for research use; cell culture apparatus for laboratory use, namely, cell culture dishes; laboratory research devices for analyzing genome information; devices for analyzing protein sequence used as laboratory apparatus; [ DNA chips; DNA microarray; ] imaging devices for scientific purposes in the field of DNA, genome, and cell information; immunostaining instruments for scientific purposes; [ incubation plates for scientific or laboratory use; ] incubators for laboratory use; diagnostic apparatus and instruments for the detection of pathogens for scientific laboratory or research use, not for medical use; laboratory incubators other than for medical use; laboratory optical inspection apparatus; [ LED microscopes; lasers for scientific use; lenses for microscopes; laboratory equipment, namely, microarray slides and microscope slides; microplate readers; analysis software for modeling DNA, genome, and cell information for scientific experiments in laboratories; ] nucleic acid sequencers for scientific purposes; [ petri dishes; petri dishes used in laboratory research; ] [ laboratory consumables, namely, pipette tips; pipettes; ] scientific apparatus and instruments, namely, spectrophotometer for measuring relative DNA, RNA and protein; [ print heads for inkjet printers; disposable plastic bioreactors for cell culture; bioreactors for cell culture; ] laboratory apparatus for fabrication of three-dimensional tissues and organs; [ scientific research and laboratory apparatus, instruments, and equipment in the field of cytology, namely, lockable petri dishes used in laboratory research; ] scientific research and laboratory apparatus, namely, [ cell handling apparatus in the nature of petri dish, ] cell separation analysis apparatus in the nature of flow cytometers and flow-based analyzers providing cell and particle analysis, detection, or counting for scientific and laboratory research uses; scientific research and laboratory apparatus, namely, cell culture apparatus for laboratory use in the nature of cell culture dishes and tissue culture flasks; biochips for use with laboratory apparatus and instruments for use in biopharmaceutical discovery and development; non-medical laboratory imaging apparatus and instruments for use in cell detection, molecular discovery, assuring cell line monoclonality, and analysis, retrieval or discovery of single cells; [ operating LED microscope stands; ] laboratory apparatus for fabrication of three dimensional (3D) living tissues; laboratory equipment for scientific and research use, namely, systems comprised of fluid dispenser, imaging station, computer hardware, control software, analysis software, chips and reagents | ACTIVE | — |
| 042 | [ Biological research, clinical research and medical research; biomedical research services; development of pharmaceutical preparations and medicines; laboratory research services relating to pharmaceuticals; laboratory research services relating to dermatology; scientific laboratory services relating to the scientific research or analysis in the field of the production of monoclonal antibodies; medical research laboratory services; medical research; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical products development; pharmaceutical research and development; pharmaceutical research services; pharmaceutical research and development for the pharmaceutical industry; research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines; scientific research and development; scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of pharmacy; pharmaceutical research services for assessing the efficiency of pharmaceuticals and veterinary drugs; testing of pharmaceuticals; research and development services in the field of antibodies; research and development in the field of microorganisms and cells; scientific services relating to the isolation and cultivation of human tissues and cells; research relating to medicines; design and development of medical diagnostic apparatus and equipment; research and development in the field of medical diagnostic preparations; research and development services in the field of cytology; biotechnology research; biotechnology testing, namely, product testing for others; research and development in the field of biotechnology; research relating to biotechnology; scientific research consulting in the field of in the field of biotechnology; scientific and medical research and development in the field of cytology; scientific and medical research and development in the field of bioprinting ] | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Cellenion SASU
- Other trademarks owned by Cellenion SASU
- Other trademarks owned by Cellenion SASU
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named CELLENION
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 6, 2026 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Jul 19, 2026 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Jul 16, 2026 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Jul 16, 2026 | INPC | INVALIDATION PROCESSED | — |
| Mar 23, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 23, 2026 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 23, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 23, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 23, 2025 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Dec 22, 2025 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Apr 23, 2025 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Apr 23, 2025 | C75P | REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Apr 20, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Dec 3, 2024 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Aug 19, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 2, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 5, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 18, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 18, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 4, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 4, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 30, 2018 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Nov 14, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 14, 2018 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 18, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 15, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Aug 29, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 29, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Aug 29, 2018 | NPUB | NOTICE OF PUBLICATION | — |
| Aug 15, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 14, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 14, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 9, 2018 | NREV | NOTICE OF REVIVAL - MAILED | — |
| Aug 9, 2018 | ALIE | ASSIGNED TO LIE | — |
| Aug 9, 2018 | PGRR | PETITION GRANTED - RESPONSE RECEIVED | — |
| Jun 28, 2018 | ERTP | TEAS RESPONSE TO PETITION DEFICIENCY RECEIVED | — |
| Jun 18, 2018 | PINM | INCOMPLETE PETITION NOTICE MAILED | — |
| Jun 8, 2018 | APET | ASSIGNED TO PETITION STAFF | — |
| Feb 1, 2018 | PETR | PETITION TO REVIVE-RECEIVED | — |
| Jan 18, 2018 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 18, 2018 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 14, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 23, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 22, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 14, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 13, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 13, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 9, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 9, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 8, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |